InvestorsObserver
×
News Home

ACADIA Pharmaceuticals Inc. (ACAD) Stock: Do Analysts Think You Should Accumulate?

Tuesday, September 14, 2021 01:00 PM | InvestorsObserver Analysts

Mentioned in this article

ACADIA Pharmaceuticals Inc. (ACAD) Stock: Do Analysts Think You Should Accumulate?

Wall Street is positive on ACADIA Pharmaceuticals Inc. (ACAD). On average, analysts give ACADIA Pharmaceuticals Inc. a Buy rating. The average price target is $25.8, which means analysts expect the stock to rise by 62.26% over the next twelve months. That average ranking earns ACADIA Pharmaceuticals Inc. an Analyst Rating of 19, which is better than 19% of stocks based on data compiled by InvestorsObserver.

Overall Score - 3.6
Wall Street analysts are rating ACAD a Buy today. Find out what this means to you and get the rest of the rankings on ACAD!

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With ACADIA Pharmaceuticals Inc. Stock Today?

ACADIA Pharmaceuticals Inc. (ACAD) stock is trading at $15.90 as of 12:58 PM on Tuesday, Sep 14, a drop of -$0.36, or -2.21% from the previous closing price of $16.26. The stock has traded between $15.81 and $16.45 so far today. Volume today is less active than usual. So far 667,782 shares have traded compared to average volume of 1,357,492 shares. Click Here to get the full Stock Report for ACADIA Pharmaceuticals Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App